MA-RENAGADE-THERAPEUTICS
27.4.2024 02:10:34 CEST | Business Wire | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.”
Formed in 2021 and invested in by ReNAgade, GanNA Bio harnesses novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center. This research was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D, M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and unlock the delivery of short and long stranded RNA medicines.
“The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients,” said Dr. Bertozzi. "The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell-specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases for RNA medicines. Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Launches NEXUS, a Converged C2 and Electromagnetic Warfare Mission System12.10.2026 13:30:00 CEST | Press release
COTS, open-architecture system brings communications, networking, edge computing, sensing and electronic effects onto a common SOSA™ and CMOSS-aligned architecture Pacific Defense, a leading provider of open-architecture C5ISR and electronic warfare mission systems, today announced the launch of NEXUS, a Commercial Off-the-Shelf (COTS) mission system that converges command and control, communications, networking, edge computing, and electronic warfare on a common, adaptable architecture. Built on a Modular Open Systems Approach (MOSA) aligned to SOSA™, CMOSS and OpenVPX™, NEXUS enables mission-specific configurations across mobile, fixed-site, maritime, and airborne operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012010656/en/ NEXUS converges EW and C5ISR in one, open-architecture system for missions across ground, maritime, and airborne operations. NEXUS brings capabilities traditionally integrated through sep
Trading Central Expands UCITS ETF Range to U.S. and Global Equities12.10.2026 13:24:00 CEST | Press release
Three funds powered by TC Quantamental Rating® are now available to brokers and distributors across Europe. Trading Central SA ("Trading Central") today announced the launch of two new UCITS ETFs in partnership with HANetf, Europe’s first and leading white-label UCITS ETF and ETC platform. The new funds join the Trading Central Quant Europe 50 Equity UCITS ETF (TCQE), launched on 13 August 2026, bringing the Trading Central Quant ETF range to three. NEW – Trading Central Quant U.S. 50 Equity UCITS ETF (TCQU) | ISIN: IE000M5KXSP3 NEW – Trading Central Quant Global 50 Equity UCITS ETF (TCQW) | ISIN: IE000YM4FP49 Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) | ISIN: IE000DN0XQM1 All three ETFs are available to trade on Euronext Paris, Euronext Milan, Euronext Dublin, the London Stock Exchange, and Börse Frankfurt. J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This launch marks Trading Central’s continued expans
Sharjah Innovation Park Launches Advanced AI Industrial Accelerator for the Super Intelligence Era12.10.2026 13:18:00 CEST | Press release
Sharjah Research, Technology and Innovation Park (SPARK) has launched the Sharjah Advanced AI Industrial Accelerator at AI Everything Abu Dhabi, introducing a global platform to attract, accelerate and scale high-potential AI-driven industrial companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012138683/en/ Hussain Al Mahmoudi during the launch of the Sharjah Advanced AI Industrial Accelerator at AI Everything Abu Dhabi 2026. (Photo: AETOSWire) Built under the theme “Towards the Super Intelligence Era,” aims to turn AI research, models and algorithms into real-world industrial applications, products, pilots and scalable businesses. Participating companies will gain access to industrial testbeds, advanced prototyping and fabrication, laboratories, applied R&D facilities, specialist mentorship, licensing and business setup support, investor connections and market-access opportunities through the SPARK ecosystem, in a
L&T Technology Services Launches EI Lab for Manufacturing and Operations, Featuring NVIDIA Accelerated AI-Native Factory12.10.2026 13:06:00 CEST | Press release
Highlights:Showcases LTTS’ Engineering Intelligence solutions across autonomous manufacturing, industrial robotics, supply chain, energy & emissions and asset reliabilityFeatures NVIDIA accelerated digital twins, Industrial AI and Physical AI for simulation, validation and increasingly autonomous field ops L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions and ER&D services, today inaugurated its AI-Native EI Lab for Digital Manufacturing in Bengaluru, an experiential environment where customers and partners can see AI-Native Manufacturing, digital twins and autonomous systems working together across the lifecycles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011660276/en/ Inauguration of the EI Lab for Manufacturing and Operations at LTTS’ Bengaluru Campus The EI Lab extends LTTS’ Engineering Intelligence charter to the manufacturing shop floor. Through live and sce
Heaviside Industries Unveils the TYR Loitering Munition, A Five-Pound Tank-Killer12.10.2026 12:00:00 CEST | Press release
With speeds over 150 mph and four modular warheads, TYR sets a new bar for performance-to-weight and man-packable lethality, extending standoff distance for warfighters Heaviside Industries, a builder of multi-domain precision munitions platforms, today introduced its TYR miniaturized loitering munition at the AUSA Annual Meeting & Exposition in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012159239/en/ The first in Heaviside’s line of precision munitions, TYR delivers outsized performance for its weight, combining speed, endurance, and lethal effects in a truly man-packable system. Weighing just over five pounds with a total system weight of approximately 15 pounds, TYR can defeat a wide range of targets, including main battle tanks. TYR offers four Nammo warhead variants — Shaped Charge Anti-Tank, Anti-Structure Munition, Explosively Formed Penetrator, and Anti-Personnel Frag — allowing warfighters to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom